From the FDA Drug Label
The FDA drug label does not answer the question.
From the Research
The full effects of increasing Jardiance (empagliflozin) from 10 mg to 25 mg typically take about 1-2 weeks to become fully apparent, as the body needs time to adjust to the higher dose and establish a new equilibrium 1. You may notice some changes in blood glucose levels within a few days, but the maximum glucose-lowering effect and other benefits like weight loss and blood pressure reduction will develop gradually over this period. This timeline occurs because Jardiance works by helping your kidneys remove excess sugar through urine. During this transition period, continue monitoring your blood glucose levels closely as directed by your healthcare provider, stay well-hydrated, and watch for any side effects such as genital infections or urinary tract infections, which can be more common at higher doses. The 25 mg dose provides additional glucose-lowering benefits compared to the 10 mg dose for many patients, though individual responses may vary based on factors like kidney function and overall health status.
Some key points to consider when increasing the dose of Jardiance include:
- Monitoring for potential side effects, such as increased risk of diabetic ketoacidosis (DKA) 2
- Adjusting the dose based on individual patient response and kidney function
- Continuing to monitor blood glucose levels and adjusting treatment as needed to achieve optimal glycemic control
- Being aware of the potential benefits of the 25 mg dose, including greater reductions in HbA1c and body weight compared to the 10 mg dose 3
It's also important to note that the safety and efficacy of empagliflozin have been extensively studied, and it has been shown to have a favorable safety profile compared to other glucose-lowering agents, such as DPP-4 inhibitors 4. However, as with any medication, it's essential to weigh the potential benefits and risks and to closely monitor patients for any adverse effects.
In terms of specific guidance, it's recommended to closely monitor patients during the transition period and to adjust the dose as needed to minimize the risk of adverse effects 1. Additionally, patients should be educated on the potential benefits and risks of the 25 mg dose and should be encouraged to report any side effects or concerns to their healthcare provider.